The FDA's decision to call an ODAC meeting for a trial that met its primary endpoint is a strong signal of agency concern. It indicates significant reservations about the drug's overall benefit-risk profile, particularly the modest efficacy, high toxicity, and lack of an overwhelming survival advantage.
An expert oncologist stated that if the drug is approved, he would not use it broadly. He would reserve it for a highly selective niche of high-risk patients who fail initial therapies and have specific NGS biomarkers. This signals a potential disconnect between a formal approval and real-world clinical utility.
The advisory panel rationalized approving a drug with 60% grade 3 toxicity by calling the side effects "manageable." This common industry term can downplay the significant, long-term clinical burden on patients—like insulin-requiring diabetes—especially when the drug's efficacy benefit is not overwhelming or life-extending.
A potential unstated argument for approving capivasertib, despite its borderline data, was the fear that a rejection would kill the entire field of AKT inhibitors. This suggests that broader strategic concerns about fostering innovation can sometimes influence regulatory recommendations more than a single drug's specific risk-benefit profile.
The drug is already approved in breast cancer with a stronger PFS benefit (HR 0.5-0.6) and lower toxicity. Its weaker data in prostate cancer (HR 0.81, 60% grade 3 toxicity) demonstrates that the same drug faces a much higher regulatory bar when the benefit-risk calculation is less favorable in a new disease context.